Peptide CDMO Capacity Expansion Surges Past $2.4B in 2026 as Demand Outpaces Global Supply

A Manufacturing Boom Unlike Any Before

The peptide contract development and manufacturing organization (CDMO) industry is in the middle of its most significant buildout in history. Through the first five months of 2026, publicly announced capital expenditure commitments from the sector's largest players have surpassed $2.4 billion and a figure that would have seemed implausible even three years ago, before GLP-1 agonists rewrote the commercial calculus of the entire peptide supply chain.

The drivers are well understood at this point: semaglutide and tirzepatide have generated unprecedented commercial demand, while a deep and broadening pipeline of peptide drug candidates and spanning metabolic disease, oncology, cardiovascular indications, and rare diseases and has convinced CDMOs that this is not a cyclical uptick but a structural shift in pharmaceutical manufacturing.

What is less well understood is the operational reality behind these announcements. Capital is necessary but not sufficient. The equipment must be procured, installed, and validated. Processes must be transferred and scaled. And critically, the people who can perform this work at commercial quality standards must be recruited, trained, and retained. On all three dimensions, the industry is stretched thin.

By the numbers: The global peptide API market is projected to reach $47.3B by 2028, up from $29.1B in 2024 and a CAGR of approximately 12.8%, driven disproportionately by GLP-1 class compounds and oncology peptide conjugates.

Who Is Building and What They Are Adding

Lonza remains the sector's most aggressive expander. The Basel-headquartered CDMO announced in February 2026 a CHF 650 million investment in large-scale solid-phase peptide synthesis (SPPS) capacity across its Visp, Switzerland and Geleen, Netherlands sites. The Visp expansion alone adds four multi-hundred-kilogram synthesis trains and a dedicated lyophilization suite with 50,000-liter freeze-dry capacity. Commercial operations are targeted for Q3 2028. Lonza is simultaneously expanding its peptide fill-finish capabilities in Stein, Switzerland, responding to client demand for fully integrated drug product manufacturing rather than API-only supply.

Bachem, often called the "backbone of the peptide industry," has been in near-continuous expansion mode since 2022. Its Campus Sisseln project in Switzerland and a greenfield site adding approximately 10,000 square meters of synthesis and purification space and is now entering its second phase, with a CHF 280 million tranche announced in March 2026 covering additional HPLC purification trains and a new building dedicated to high-potency peptide manufacturing with contained handling capabilities. Bachem's revenue from manufacturing services grew 31% year-over-year in 2025, and management has signaled that order books remain constrained by capacity, not demand.

PolyPeptide Group, which operates manufacturing sites across Sweden, France, India, and the United States, announced a $180 million expansion plan in January 2026 with a particular emphasis on its Strasbourg, France facility. The investment adds large-scale SPPS capability for kilogram-to-metric-ton quantities and expands the site's lyophilization footprint. Notably, PolyPeptide is also investing in continuous manufacturing infrastructure, positioning itself as an early mover in next-generation peptide production technology that regulators have begun to actively encourage.

Almac Group, based in Craigavon, Northern Ireland, announced a £95 million investment in its peptide synthesis and bioconjugation capabilities in Q1 2026. Almac has carved out a differentiated position in peptide-drug conjugates (PDCs) and targeted radiopharmaceuticals, two of the fastest-growing adjacent segments in the sector. The expansion includes dedicated GMP suites for antibody-peptide conjugation and radiolabeling, capabilities that are currently bottlenecked across the entire industry.

Thermo Fisher Scientific announced a $420 million investment in peptide API manufacturing in March 2026, distributed across its Greenville, North Carolina and Ferentino, Italy sites. The Greenville investment is particularly significant from a geopolitical perspective and it represents a deliberate reshoring of North American peptide supply chain capacity as customers seek supply chain resilience amid ongoing concerns about concentration risk in Asian manufacturing.

and Senior Vice President, Business Development, Large-Scale CDMO: "We are seeing customers commit to multi-year capacity reservations two to three years before the capacity even exists. That level of forward commitment is unprecedented in our industry and tells you how seriously pharmaceutical companies are taking supply security"

Why Demand Is Structurally Outpacing Supply

The supply-demand imbalance in peptide manufacturing is not simply a function of GLP-1 scale. It reflects a broader reality: the pharmaceutical industry spent the better part of a decade underinvesting in peptide manufacturing infrastructure, assuming that small molecules and biologics would continue to dominate new drug approvals. That assumption proved incorrect.

Between 2022 and 2026, the FDA approved or granted breakthrough designation to over 40 peptide-based therapeutics, spanning indications from obesity to prostate cancer. Each of these programs requires manufacturing capacity at successively larger scales as clinical development progresses and and many are now entering Phase 3 or commercial launch simultaneously.

SPPS capacity is particularly constrained because large-scale synthesis equipment has lead times of 14-22 months from order to delivery, and the number of manufacturers globally who produce peptide synthesis equipment at commercial scale is limited. Lyophilization and the freeze-drying process that converts liquid peptide solutions into stable solid dosage forms and faces similar constraints, with industrial-scale lyophilizers requiring 18-24 months for procurement and qualification.

The result is a market where even well-capitalized CDMOs cannot bring new capacity online as fast as customers need it, creating a window of significant pricing power and, for pharmaceutical companies, a strategic imperative to secure capacity through long-term supply agreements.

By the numbers: Industry analysts estimate that global peptide API manufacturing capacity utilization currently runs at approximately 87-91%, compared to a sustainable long-run average closer to 70-75%. At these utilization rates, any demand surge or supply disruption can rapidly create shortages.

The Talent Constraint No One Is Talking About Enough

Capital announcements generate headlines. Hiring plans receive far less attention, but they may matter more for determining which CDMOs can actually deliver on their expansion promises.

Large-scale peptide manufacturing requires a specific and not-easily-sourced skill set. Process chemists who understand the nuances of SPPS at kilogram-to-metric-ton scale and resin loading optimization, coupling efficiency at scale, purification by preparative HPLC and are trained primarily through direct industry experience. Universities produce analytical chemists and synthetic chemists; the peptide manufacturing specialization comes on the job. This creates a shallow talent pool that the entire industry is simultaneously trying to hire from.

Lyophilization engineers represent another critical gap. Freeze-drying at commercial scale is technically complex, requires deep process knowledge, and is subject to intensive FDA and EMA regulatory scrutiny. There are perhaps a few hundred true lyophilization experts globally with GMP manufacturing experience. Every CDMO building new freeze-drying capacity needs them.

QA/QC professionals with peptide-specific experience and understanding impurity profiles, method development for complex peptide APIs, batch record management under GMP compliance frameworks and are also in critically short supply. As CDMOs bring new facilities online, they must staff quality functions before manufacturing can begin, creating a front-loaded hiring demand that is difficult to meet from the existing talent pool.

For outsourcing services decisions, pharmaceutical companies are increasingly asking CDMOs not just about square footage and equipment, but about workforce stability and hiring pipelines and recognizing that unstaffed capacity is not useful capacity.

What This Means for the Industry Through 2028

The $2.4 billion in announced expansions will not solve the supply crunch immediately. Given equipment lead times, construction timelines, and validation requirements, the bulk of new capacity will not become commercially available until 2027-2029. In the interim, the industry faces a period of constrained supply, elevated pricing, and intense competition for manufacturing slots.

For pharmaceutical companies with peptide programs advancing toward commercialization, the implication is clear: engage CDMOs early, consider capacity reservations and strategic partnerships rather than transactional spot purchasing, and build supply chain redundancy where possible. The peptide synthesis process optimization decisions made today will determine launch readiness two to three years from now.

For CDMOs themselves, the constraint is increasingly human rather than financial. The companies that invest in workforce development, build strong academic partnerships, and create compelling retention programs for scarce technical talent will be best positioned to convert their capital investments into operational reality and and into the long-term customer relationships that will define the competitive landscape of peptide manufacturing for the decade ahead.

Conclusion

The $2.4 billion CDMO expansion wave of 2026 represents a generational investment in peptide manufacturing infrastructure, driven by the convergence of GLP-1 commercial scale and a broadening pipeline of therapeutic peptides. Lonza, Bachem, PolyPeptide, Almac, and Thermo Fisher are each executing ambitious buildouts that will reshape the industry's capacity profile by the end of the decade. But capital alone does not manufacture peptides. The ultimate determinant of who wins in this environment will be the ability to attract, develop, and retain the specialized technical workforce that can turn new facilities into productive, GMP-compliant manufacturing operations. In a market where talent is already the scarcest input, that competition is only going to intensify.